Human gingival glycosaminoglycans in cyclosporin-induced overgrowth.
Glycosaminoglycans in normal and cyclosporin-induced gingival overgrowth were extracted by papain digestion and purified by Mono Q-FPLC chromatography. The purified glycosaminoglycans were analyzed by agarose gel electrophoresis and by the pattern of degradation products formed by chondroitin lyases on HPLC chromatography. Our results on the glycosaminoglycan composition showed presence of chondroitin 4- and 6-sulfate, dermatan sulfate, heparan sulfate and hyaluronic acid in both normal gingiva and cyclosporin-induced gingival overgrowth. The total and relative amounts of glycosaminoglycans were similar between normal and overgrown gingiva. This suggests that the glycosaminoglycan composition is not changed in cyclosporin-induced gingival overgrowth. Our present biochemical results conflict with histochemical and biosynthetic data previously reported by other groups. Those studies suggested that the affected tissues contained higher levels of glycosaminoglycans and that cyclosporin induced comparably high levels of these compounds in in vitro cultures of gingival fibroblasts. Therefore, these discrepant results suggest that a cyclosporin-induced increase on gingival glycosaminoglycans still remains an open question. The implications of these conflicting results are discussed.
Faculdade de Odontologia, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Brazil.
L A
LA
Rocha
R C
RC
Martins
C C
CC
Werneck
E J
EJ
Feres-Filho
L C
LC
Silva
D000328:Adult; D002809:Chondroitin Sulfates / Q000032:analysis; D002851:Chromatography, High Pressure Liquid; D016572:Cyclosporine / Q000009:adverse effects*; D003871:Dermatan Sulfate / Q000032:analysis; D004587:Electrophoresis, Agar Gel; D016326:Extracellular Matrix Proteins / Q000032:analysis; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000378:metabolism*; D006025:Glycosaminoglycans / Q000032:analysis*; D006497:Heparan Sulfate / Q000032:analysis; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged
D002809:Chondroitin Sulfates; D016572:Cyclosporine; D003871:Dermatan Sulfate; D016326:Extracellular Matrix Proteins; D006025:Glycosaminoglycans; D006497:Heparan Sulfate; D006820:Hyaluronic Acid; D007166:Immunosuppressive Agents